New strategic alliance underscores Komodo’s entry into the agency space to help extend the reach of its Healthcare MapTM to more life sciences brands
Komodo Health and Klick Health today announced a strategic partnership making Klick the premier life sciences marketing agency to leverage Komodo’s Healthcare MapTM – a real-world data and analytics platform. The alliance will give Klick clients access to the industry’s most complete view of anonymized patient encounters and enable demonstrably more insightful and targeted healthcare marketing programs.
With Klick as the leading commercialization partner for a growing number of life sciences companies, today’s announcement reinforces the value Klick offers its clients to enhance health outcomes across a wide array of therapeutic areas. The news also bolsters Komodo’s continued market growth as a foundational enterprise technology platform, designed to connect the dots between individual patient journeys and large-scale health outcomes.
“We are thrilled to work with Klick to extend our unique capabilities in support of their life sciences clients,” said Komodo Co-Founder and CEO Arif Nathoo, MD. “There are a lot of synergies between our entrepreneurial organizations, and together we can help marketers navigate today’s complex healthcare landscape using our advanced analytics and intelligence tools.”
Klick Co-Founder and Chairman Leerom Segal said, “Our strategic partnership with Komodo is a real game-changer, giving our clients the best healthcare intelligence for optimizing program and campaign design, delivery, and performance. It’s also a great example of how we keep leaning into our digital roots and adopting the latest data-driven approaches to give our clients a competitive edge and make a positive difference in health.”
Komodo’s Healthcare MapTM integrates disparate sources of patient-level data to provide the industry’s most precise view of the U.S. healthcare system. The platform provides the critical insights necessary to optimize commercial strategy, analyze competitive market share, and identify the key decision makers essential for driving treatment decisions. It is helping the world’s leading life sciences companies, health plans, and patient advocacy groups close gaps in care, address unmet patient needs, improve engagement, and ultimately help drive novel therapies into the market.
Last month, Komodo Health announced $220 million in Series E funding to further accelerate its growth.
